New dual-action vaccine against original SARS-CoV-2 strain and Omicron variant
Moderna’s novel bivalent vaccine is the first of its kind to be approved by the UK Medicines and Healthcare Products Regulatory Agency in the fight against the COVID-19 pandemic and SARS-CoV-2 variants.
The UK has become the first country to approve Moderna’s novel bivalent vaccine against the original SARS-CoV-2 virus strain and the recent Omicron variant, which will form a part of the country’s autumn booster campaign.
With the Omicron variant of the SARS-CoV-2 virus responsible for the large surge in COVID-19 cases around the world since December 2021, Moderna’s latest vaccine – termed Spikevax – aims to target both the original viral strain as well as the first Omicron variant BA.1, a type of vaccine known as a bivalent vaccine. The vaccine arrives on the heels of multiple new strains of the original coronavirus responsible for the COVID-19 pandemic.
The Medicines and Healthcare Products Regulatory Agency in the UK has considered the evidence, including experiments on 437 individuals demonstrating the safety of the vaccine and their increased immunity against variants of SARS-CoV-2. It was discovered that the levels of antibodies able to detect and bind to the BA.1 Omicron variant were 1.7 times higher in those who were administered the new vaccine. Antibodies against more recent Omicron variants, BA.4 and BA.5, which are responsible for the current wave of UK cases, were also present in higher levels.
June Raine, the regulatory agency’s Chief Executive, commented: “What this bivalent vaccine gives us is a sharpened tool in our armoury to help protect us against this disease as the virus continues to evolve.”
However, the experiments are not without uncertainties. It is unclear whether the higher levels of antibodies provided by the vaccine equate to the prevention of serious illness, or whether it rules out the possibilities of new variants in the future. It is unknown whether an updated vaccine will be required and how effective they will be.
For now, health ministers in the UK remain optimistic regarding the bivalent vaccine and plans for an autumn booster campaign. CEO of Moderna Stephane Bancel stated: “This represents the first authorisation of an Omicron-containing bivalent vaccine – this bivalent vaccine has an important role to play in protecting people in the UK from COVID-19 as we enter the winter months.”
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance